Related Experiment Video

Updated: Apr 5, 2026

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
07:35

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

7.5K

[Molecular biology of colorectal cancer in clinical practice]

O I Kit1, D I Vodolazhsky1,2

  • 1Rostov Research Institute of Oncology of the Ministry of Healthcare of the Russian Federation, Rostov-on-Don, 344037 Russia.

Molekuliarnaia Biologiia
|August 25, 2015
PubMed

Insights

This review explores colorectal cancer (CRC) molecular genetics and biomarkers. It highlights microRNA roles in CRC pathogenesis and identifies potential therapeutic targets for improved patient outcomes.

Area of Science:

  • Molecular biology
  • Genetics
  • Oncology

Context:

  • Colorectal cancer (CRC) pathogenesis involves complex molecular genetic mechanisms.
  • Biomarkers are crucial for CRC diagnosis, risk stratification, prognosis, and treatment response prediction.
  • MicroRNAs play a significant role in regulating key signaling pathways implicated in CRC.

Purpose:

  • To review current data on molecular genetic mechanisms in CRC pathogenesis.
  • To connect these mechanisms with clinically relevant biomarkers.
  • To examine signaling pathways as potential therapeutic targets in CRC.

Summary:

  • The review synthesizes information on the molecular genetic underpinnings of colorectal cancer.
  • It details the association between these genetic factors and biomarkers for diagnosis, prognosis, and treatment selection.
  • The role of microRNAs in regulating CRC-associated signaling pathways is discussed.
  • Potential therapeutic targets within these signaling pathways are identified.

Impact:

  • Provides a comprehensive overview of CRC molecular genetics and biomarker associations.
  • Identifies microRNAs as key regulators in CRC development.
  • Highlights promising signaling pathways for targeted colorectal cancer therapy.
  • Aims to improve predictive diagnosis, risk stratification, and treatment strategies for CRC patients.
Keywords:
CIMPEGFRKRASTGF-ßWNTbiomarkerchromosomal instabilitycolorectal cancer (CRC)microRNAmicrosatellite instabilitysignaling pathwaytargeted therapy

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

6.1K
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.8K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.9K